Automated alerts from Tempus improve outcomes for patients with valvular heart disease

Automated alerts from the Tempus Next platform are transforming care for patients with valvular heart disease by providing real-time data to clinicians, enabling faster assessments, increasing timely surgeries, and promoting equitable access to life-saving treatments worldwide.

Data-driven insights, powered by advanced intelligence, are revolutionizing the treatment journey for individuals dealing with valve-related heart conditions. This transformation is possible through a collaborative innovation between Tempus and Medtronic, offering a path to improved health and equity in patient care.

Overview of the ALERT Study

The ALERT study (NCT06099665) is a cluster-randomized, interventional research trial designed to evaluate the impact of automated alerts from the Tempus Next platform on patient care. Specifically, the study focused on patients with mitral regurgitation (MR) and aortic stenosis (AS). The research explored how the digitization of patient pathways, facilitated by the Tempus Next system, could enhance the management of cardiovascular diseases. The primary goal was to determine whether electronic health records (EHRs) could streamline care processes and provide quicker access to necessary treatments.

Key Findings from the Study

The ALERT study revealed significant improvements in patient care, driven by timely digital notifications from the Tempus Next platform. One of the major findings was a 27% increase in the likelihood of patients receiving a comprehensive cardiac assessment during the critical first three months of treatment. This boost played a pivotal role in the study’s core objective of improving patient outcomes.

Furthermore, the Tempus Next system had a remarkable impact on the volume of valve surgeries. The platform contributed to a 40% increase in the number of surgeries, with a thirteen-fold surge in surgical procedures. As a result, one in twenty patients experienced positive outcomes after receiving treatment, compared to one in eleven patients without such intervention. This stands in stark contrast to the mere 6% improvement seen with standard treatment methods.

How the Tempus Next Platform Works

The Tempus Next system operates by processing echocardiogram reports, identifying crucial real-time data, and generating automatic notifications for clinicians regarding the patient’s cardiovascular status. These timely alerts enable healthcare providers to make swift decisions, thereby improving patient outcomes and ensuring more effective treatment plans.

Promoting Equity in Cardiovascular Care

Despite advancements in cardiovascular treatments, there remain significant disparities in access to care, especially for patients with MR and AS. Kendra Grubb, Vice President and Chief Medical Officer of Medtronic's Structural Heart division, highlighted the role of technologies like Tempus Next in addressing these disparities. By ensuring timely evaluation and facilitating access to life-saving treatments, Tempus Next helps to reduce barriers to care and promotes equity in cardiovascular healthcare.

The Tempus Next platform plays a critical role in bridging the gaps in patient care by leveraging electronic health records to provide a streamlined, standardized, and accessible treatment process. This system enables consistent care across diverse patient populations, contributing to improved outcomes for individuals affected by heart disease.

Market Trends in Health Technology

Cloud-based systems are currently leading the market for electronic health records (EHR) in the EU5 countries—France, Germany, Italy, Spain, and the UK—in terms of revenue. As the demand for remote EHR systems continues to grow, it is expected that by 2033, such systems will account for 39% of the market share. Additionally, the digital health sector is witnessing a surge in regulatory-focused applications, with double-digit growth expected for these tools between 2024 and 2034, as forecasted by GlobalData.

AI and the Future of Cardiovascular Care

The ALERT study demonstrated how artificial intelligence is revolutionizing the field of heart disease. By accelerating diagnoses, expanding access to critical treatments, and ensuring consistent care delivery, AI technologies like Tempus Next are reshaping the future of cardiovascular care. These advancements promise to level the playing field for patients worldwide, offering more timely, equitable, and efficient healthcare solutions.

The Potential of Advanced Technology

The Tempus Next platform exemplifies the potential of integrating cutting-edge technology with electronic health records to create a more efficient and patient-centered healthcare system. By leveraging real-time data and automating key aspects of care, this system has the power to improve outcomes for patients globally, highlighting the important role of digital health in transforming the landscape of healthcare delivery.

Sources:

• Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease
• Tempus’ automated alerts boost patient outcomes in valvular heart disease - Clinical Trials Arena
• Tempus AI trial shows automated alerts improve heart valve care - Investing.com
• Tempus’ automated alerts boost patient outcomes in valvular heart disease